Perioperative Immunotherapy for Non-small Cell Lung Cancer:a Review of Neoadjuvant and Adjuvant Immunotherapy
As a common subtype of lung cancer,non-small cell lung cancer(NSCLC)causes a high mortality rate.Surgery is the main treatment for early to mid-stage NSCLC,but stage ⅡB-Ⅲ patients are at high risk of recurrence,and there is an urgent need to explore effective perioper-ative therapeutic options to improve the survival prognosis of patients.The emergence of immune checkpoint inhibitors(ICIs)has gradually made immunotherapy a research focus for the perioper-ative treatment of many types of cancers,and many clinical trials of immunotherapy for periopera-tive NSCLC patients have emerged in recent years.The clinical application of immunotherapy has also brought about many pending issues that require in-depth discussion.This article reviews the clinical research and progress related to the application of neoadjuvant,adjuvant immunotherapy and new modalities of immunotherapy in the perioperative period of NSCLC.
万方数据
维普
